Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-20-100979
Filing Date
2020-09-01
Accepted
2020-08-31 20:10:06
Documents
1
Effectiveness Date
2020-09-01

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2029945d1_8k.htm DEFA14A 17062
  Complete submission text file 0001104659-20-100979.txt   18113
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-13341 | Film No.: 201153074
SIC: 2836 Biological Products, (No Diagnostic Substances)